<DOC>
	<DOCNO>NCT00723645</DOCNO>
	<brief_summary>This observational , multicenter , nationwide study information collect follow-up participant chronic hepatitis C virus ( HCV ) viral response end treatment pegylated interferon alfa-2b ( PEG IFN alfa-2b ) plus ribavirin ( RBV ) administer accord direction product ' labeling . No administration treatment plan result study enrollment .</brief_summary>
	<brief_title>Rate Predictors Relapse Treatment Hepatitis C ( Study P05181 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Participants chronic hepatitis C virus ( HCV ) [ genotype ] receive pegylated interferon alfa2b plus ribavirin first treatment hepatitis C. Negative HCV RNA end treatment ( 24 48 week accord product label appropriate ) , measure assay use institution . Only institution use assay limit detection 50 IU/mL less eligible . Women childbearing potential ( i.e. , premenopausal woman woman le 6 month postmenopausal ) use appropriate contraceptive method course clinical study . Appropriate contraceptive include double barrier method ( eg , diaphragm condom plus spermicide ) , intrauterine device , oral , injectable subcutaneous hormonal contraceptive , surgically sterilized partner . Completed treatment pegylated interferon alfa2b plus ribavirin 4 week study entry . Positive HCV RNA end treatment ( 24 48 week accord product label appropriate ) . Participants treat period shorter enrollment period . Coinfection Human Immumodeficiency Virus ( HIV ) . Coinfected Hepatitis B Virus ( HBV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>